In January 2009, Pfizer announced its acquisition of Wyeth in a cash and stock deal valued at $68 billion. This deal represented the first mega-acquisition since the world economic crisis, which commenced in September 2008.
Jeff Kindler knew that the last acquisition (Pharmacia in 2003) had not gone as planned. Was Pfizer prepared for the Wyeth acquisition? Would it create new ones or solve some of the urgent problems of Pfizer?
PUBLICATION DATE: February 17, 2011 PRODUCT #: 910M53-PDF-ENG
This is just an excerpt. This case is about LEADERSHIP & MANAGING PEOPLE